ArticleJournal of rheumatic diseases2025
Validity of a claim-based algorithm for classifying disease activity levels using Systemic Lupus Erythematosus Disease Activity Index 2000 in Korean patients with systemic lupus erythematosus.
Article in Journal of rheumatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Long-Term Safety and Efficacy of Anifrolumab in Systemic Lupus Erythematosus: A Meta-Analysis of Randomized Controlled Trials, Extension Studies, and Real-World Cohorts.Pharmacology · 2026Pooled it
- Precision and contextualization in claims-based disease activity assessment for systemic lupus erythematosus in Korean populations.Journal of rheumatic diseases · 2026Article
- Repeat kidney biopsy in pediatric lupus nephritis: an analysis of associated clinical-pathological features and outcomes.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To validate algorithms for classifying disease activity in patients with systemic lupus erythematosus (SLE) using Korean claims data. Methods: We used data from a prospective cohort of SLE patients enrolled at a single academic center between October 2014 and August 2020. Disease activity was assessed at each visit using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), with the annual average score serving as the gold standard. Three claims-based algorithms incorporating diagnostic codes for comorbidities and medication use were evaluated (1) a previously established model including SLE-related comorbidities, immunosuppressants, and oral glucocorticoids, (2) a modified version incorporating intravenous glucocorticoids, and (3) a version with adjusted glucocorticoid dosage criteria (5 mg) to better identify mild to moderate disease. The performance of each algorithm in classifying mild disease activity-defined as SLEDAI-2K <3-was assessed by calculating sensitivity, specificity, positive predictive value (PPV), negative predictive value, and the area under the curve. Results: A total of 151 patients were included. The mean age was 34.5±8.7 years, and 94.7% were female. The mean initial SLEDAI-2K score was 3.6±2.6. The PPV for identifying mild disease activity ranged from 75.9% to 77.2%, with Algorithm 3 demonstrating the highest PPV. However, incorporating intravenous glucocorticoids or adjusting dosage thresholds did not result in further improvement. Conclusion: A claims-based algorithm using diagnostic and medication codes demonstrated a PPV of 77.2% for classifying mild disease activity in SLE. This approach may offer a practical method for disease activity assessment in Korean claims-based research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.